AZD2265 (FPI-2265)
D7642C00001
Phase 2 small_molecule active
Quick answer
AZD2265 (FPI-2265) for Metastatic Prostate Cancer is a Phase 2 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca
- Indication
- Metastatic Prostate Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active